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Complement is traditionally thought of as aproinflam-
matory effector mechanism of antitumor immunity.
However, complement is also important for effective
clearance of apoptotic cells, which can be an anti-in-
flammatory and tolerogenic process. We show that
localized fractionated radiation therapy (RT) of sub-
cutaneous murine lymphoma results in tumor cell
apoptosis and local complement activation. Cotreat-
ment of mice with tumor-targeted complement inhi-
bition markedly improved therapeutic outcome of
RT, an effect linked to early increases in apoptotic
cell numbers and increased inflammation. Improved
outcome was dependent on an early neutrophil influx
and was characterized by increased numbers of
maturedendriticcells and thesubsequentmodulation
of T cell immunity. Appropriate complement inhibition
maybe apromising strategy to enhance amainstay of
treatment for cancer.INTRODUCTION
Radiation therapy (RT) is amainstay of treatment for manymalig-
nancies and is frequently used as primary or adjuvant therapy,
often in combination with surgery or chemotherapy or both.
Whereas RT causes direct tumor cell death, an emerging para-
digm is that the antitumor effects of RT also depend to a varying
extent on the immune system, with RT able to modulate the
immune response via its effect on the release of damage-asso-
ciated molecular patterns (DAMPs). Nevertheless, the mecha-
nisms by which RT modulates either an innate or an adaptive
antitumor immune response remain largely unknown, and it is
likely that different mechanisms operate depending on the type
of cancer and RT dose.
Direct killing of tumor cells by RT is due to irreversible DNA
damage, which leads to the induction of cellular senescence,
mitotic catastrophe, necrosis, and/or apoptosis. Apoptosis rep-
resents a major form of radiation-induced cell death, especially
for some types of cancer such as lymphoma, but in terms818 Cell Reports 8, 818–830, August 7, 2014 ª2014 The Authorsof an RT-induced immune response, apoptosis is generally
considered noninflammatory and is physiologically designed to
preserve immunological tolerance. In the context of cancer,
however, a general immunotherapeutic goal is to break tolerance
to tumor-associated antigens. Although apoptotic cell death can
be inflammatory depending on how it is activated and in what cell
types, necrotic cell death results in a more sustained and power-
ful inflammatory response, with increased production of DAMPs
and a skewing of proinflammatory cytokines and chemokines
released by stimulated phagocytes. Impaired apoptotic cell
clearance can lead to secondary necrosis, and the recognition
and clearance of necrotic cells is a highly immunogenic
process. There is strong evidence indicating that uncleared
apoptotic cells are a source of immunogenic self-antigens and
can lead to autoimmunization.
The complement system is a keymediator of inflammation, but
it also plays an important role in promoting the clearance of
apoptotic cells, which can be an anti-inflammatory and tolero-
genic process. Complement activation can occur via the clas-
sical, lectin, or alternative pathways, all of which converge at
the cleavage of C3 and the subsequent generation of various
biologically active fragments. Complement activation by any
pathway leads to opsonization of target cells with the C3 activa-
tion products iC3b and C3d, which have been shown to promote
C3 receptor-dependent phagocytic clearance of apoptotic cells
(Mevorach et al., 1998). In addition, C1q andMBL not only initiate
the classical and lectin pathways, respectively (resulting in C3
opsonization), but also function directly as serum opsonins for
phagocytosis (Ogden et al., 2001; Tenner, 1998). C1q can bind
directly (albeit weakly) to apoptotic cell membranes (Korb and
Ahearn, 1997; Navratil et al., 2001), but both C1q and MBL
bind natural immunoglobulin M (IgM) antibodies that recognize
neoepitopes exposed on apoptotic cells (Chen et al., 2009; Sil-
verman et al., 2009). Properdin can also bind apoptotic cells
and initiate the alternative pathway to promote C3-dependent
phagocytosis (Kemper et al., 2008), and C-reactive protein
can bind to apoptotic cells and activate the classical pathway
(Gershov et al., 2000).
Traditional lines of study with regard to cancer and comple-
ment have focused on strategies to enhance complement
activation on cancer cells. However, we hypothesized that in
the context of RT, inhibiting complement activation will improve
therapeutic outcome by interfering with the phagocytic uptake
of apoptotic cells, leading to increased necrotic burden and
the formation of a more immunogenic tumor environment. We
investigated this hypothesis using a mouse model of lymphoma,
a generally radiosensitive type of cancer in which tumor cell
apoptosis is known to occur following fractionated RT. To inhibit
complement, we utilized CR2-Crry, a targeted inhibitor that
blocks all complement pathways at the C3 activation step. The
CR2moiety of the fusion protein binds to deposited C3 cleavage
products and thus targets the construct to sites of complement
activation (Song et al., 2003), such as the surface of apoptotic
cells. The benefits of CR2-mediated targeted complement inhi-
bition versus systemic complement inhibition have been shown
previously and include improved bioavailability and efficacy
and maintenance of host immunity to infection (Atkinson et al.,
2005). A CR2 targeting strategy for complement inhibition is
currently in clinical trials for paroxysmal nocturnal hemoglobin-
uria (http://www.clinicaltrials.gov/ct2/results?term=tt30).
RESULTS
Targeted Complement Inhibition Enhances the
Therapeutic Outcome of RT
The effect of CR2-Crry on the therapeutic outcome of RT was
investigated using a subcutaneous mouse model of lymphoma
(EL4). Starting on day 12 after tumor challenge, mice received
1.5 Gy to a depth of 10 mm per treatment for a total of ten treat-
ments given over 14 days (15 Gy total). Although lymphoma
would typically be treated with a higher total dose, the fraction-
ated dose is in line with common clinical fractionation schemes,
and a pilot dose-escalation study demonstrated it was the opti-
mum dose for retardation of tumor growth with no overt signs
of toxicity in this model. CR2-Crry treatment was initiated 24 hr
after the first fraction of RT and every 3 days thereafter for the
duration of RT (Figure S1). Tumor size and survival were followed
asmarkers of treatment outcome. Survivingmicewere sacrificed
at the end of the treatment schedule (day 14). Tumor growth
rate was significantly reduced in mice receiving localized RT
compared to nonirradiated mice, but cotreatment with RT plus
CR2-Crry (RT+CR2-Crry) further reduced the tumor growth rate
(Figure 1A), with tumor burden at death or sacrifice significantly
lower inmice receiving RT+CR2-Crry compared to RT alone (Fig-
ure 1B). Furthermore, compared to mice that received RT alone,
combined RT+CR2-Crry treatment significant improved survival
at 14 days posttreatment initiation (Figure 1C). Treatment of
micewith CR2-Crry in the absence of RT had no significant effect
on tumor growth rate, tumor burden, or survival compared to un-
treated mice, demonstrating a therapeutic benefit of CR2-Crry
only in the context of RT. Consequently, a CR2-Crry alone treat-
ment group was not included in subsequent experiments.
CR2-Crry Targets to Irradiated Tumors and Inhibits
Complement
We have previously demonstrated that CR2-Crry targets and
specifically binds the C3d complement activation product
in vitro and in vivo (Atkinson et al., 2005). To investigate C3d
deposition and the targeting and retention of CR2-Crry in tu-
mors, we performed in vivo whole-animal fluorescence imaging.Tumor-bearing mice that had received either RT for 4 days at 1.5
Gy/day or no RT were injected with fluorescently labeled CR2-
Crry via the tail vein, and animals were imaged over a period of
48 hr. Labeled CR2-Crry localized to tumors in both groups of
mice, but the fluorescent signal was significantly higher in irradi-
ated tumors compared to nonirradiated tumors at all time points
(1, 5, 24, and 48 hr) (Figures 2A and 2B). CR2-Crry deposition in
tumors peaked at 24 hr in mice receiving RT and remained high
at 48 hr, whereas CR2-Crry peaked at 5 hr in nonirradiated mice
and was almost undetectable by 48 hr. The changing fluorescent
signal over time likely reflects a dynamic of ongoing complement
activation and binding of CR2-Crry from the circulation (CR2-
Crry has a circulatory half-life of 8.7 hr; Atkinson et al., 2005).
These data indicate that localized RT induces complement acti-
vation within tumors, with the subsequent targeting and locali-
zation of systemically injected CR2-Crry. At earlier time points,
some fluorescent signal was seen in the location of the liver in
irradiated and nonirradiated mice, and this may be associated
with the nonspecific clearance of the protein and possibly of
complement opsonized tumor cell debris. Increased comple-
ment activation in irradiated tumors compared to nonirradiated
tumors was also confirmed by immunohistochemical staining
for C3d and analysis of the downstream activation product
C5a in tumor homogenates. Anti-C3d staining also demon-
strated complement activation in irradiated tumors and that
CR2-Crry inhibited RT-induced complement activation (Figures
2C and 2D). It is not clear why we did not detect increased
C5a levels in tumors from irradiated versus nonirradiated mice
(Figure 2E), but CR2-Crry treatment significantly reduced C5a
levels, in line with reduced C3d deposition.
Targeted Complement Inhibition Promotes
Inflammation within Irradiated Tumors
Complement activation is normally associated with inflamma-
tion, and complement inhibition is normally anti-inflammatory,
which is not a characteristic generally associated with an anti-
tumor response. We therefore investigated whether targeted
complement inhibition modulates the inflammatory environment
within tumors after localized RT. We first investigated the profile
of select cytokines 7 days after initiation of our treatment proto-
col. Compared to tumors from nonirradiated mice, low-dose
fractionated RT had no significant effect on tumor levels of inter-
feron-g (IFN-g), interleukin-6 (IL-6), IL-17, or IL-10. However,
levels of IFN-g, IL-6, and IL-17 were significantly higher in tumors
from mice receiving combined RT+CR2-Crry compared to mice
receiving RT alone (Figure 3A). IL-10 levels were not significantly
different between any of the treatment groups.
Tumor-infiltrating macrophages (total, M1, and M2), myeloid-
derived suppressor cells (MDSCs) (granulocytic and myeloid),
natural killer (NK) cells, CD4+ T cells, CD8+ T cells, T regulatory
cells (Tregs), and neutrophils were also assessed at 7 days after
initiation of our treatment protocol. Except for neutrophils, there
were no differences in the numbers of infiltrating cells in tumors
isolated frommice receiving either RT or RT+CR2-Crry, and only
MDSCs showed an increase in irradiated compared to nonir-
radiated tumors (data not shown). CD8+ T cells and Tregs were
essentially absent in tumors from all animal groups. Neutrophil
infiltration, however, was significantly increased in tumors fromCell Reports 8, 818–830, August 7, 2014 ª2014 The Authors 819
Figure 1. Complement Inhibition with CR2-Crry Enhances the Therapeutic Effect of RT
Subcutaneous EL4 tumors were left untreated or were treated with RT alone, CR2-Crry alone, or with RT+CR2-Crry according to our treatment protocol (refer to
Figure S1).
(A) Growth of EL4 tumors over the course of 14 days from initiation of treatment protocol (individual replicates; n = 15–26).
(B) Tumor size (mm3) at time of death or sacrifice on day 14 (mean ± SEM; n = 12–26; ***p < 0.001).
(C) Survival of mice over a 14-day period from initiation of treatment protocol (n = 12–26; ***p < 0.001). Data are combined from three independent experiments,
except for Crry-alone data, which are combined from two independent experiments. The separate experiments all yielded similar results.mice receiving RT+CR2-Crry compared to RT alone, as
measured by both immunohistochemistry and myeloperoxidase
(MPO) activity (Figures 3B and 3C). Together, the above data
indicate that although complement inhibition is normally anti-in-
flammatory, in the context of RT, targeted complement inhibition
promotes a proinflammatory tumor environment.
The Effect of Complement Inhibition on Apoptotic
Tumor Cell Numbers after RT
Complement opsonization promotes the phagocytic uptake of
apoptotic cells, and the failure to clear apoptotic cells is asso-
ciated with secondary necrosis and inflammation (Kepp et al.,820 Cell Reports 8, 818–830, August 7, 2014 ª2014 The Authors2009). Since apoptosis is a major form of radiation-induced
cell death, we investigated the effect of CR2-Crry on apoptotic
cell numbers within irradiated tumors. TUNEL staining of sec-
tions from tumors isolated 7 days after initiation of our treat-
ment protocol revealed a significantly higher percentage of
apoptotic cells in tumors from mice receiving RT+CR2-Crry
compared to tumors from nonirradiated mice and mice
receiving RT alone (Figure 3D). There was no difference in
apoptotic cell numbers between nonirradiated mice and mice
receiving only RT. These data are consistent with impaired
apoptotic cell clearance in irradiated tumors from comple-
ment-inhibited mice.
Figure 2. CR2-Crry Localization and Complement Activation in Irradiated Tumors
Mice with subcutaneous EL4 tumors were treated with localized RT for 4 days or left untreated and then injected with fluorescently labeled CR2-Crry. Targeting of
CR2-Crry to irradiated and nonirradiated tumors was visualized by in vivo fluorescence tomography.
(A) Representative images (n = 3).
(B) Quantification of tumor fluorescence (mean ± SEM; n = 3; *p < 0.05 at all time points).
Tumors were removed from untreated mice 48 hr after initiation of treatment protocol (24 hr after first CR2-Crry treatment) and sections stained for C3d.
(C) Representative images (n = 6).
(D) Quantification of positive cells on scale of 0 to 3 in five high-powered fields (n = 6; *p < 0.05).
(E) C5a levels in tumors removed from mice 48 hr after initiation of treatment protocol (mean ± SEM; n = 9; *p < 0.05).
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Figure 3. The Effect of Complement Inhibi-
tion on the Early Inflammatory Response
within Tumors and Apoptotic Cell Numbers
after RT
(A) Levels of IFN-g, IL-6, IL-17, and IL-10 in tumor
homogenates 7 days posttreatment initiation.
Cytokine levels were measured by ELISA (mean ±
SEM; n = 9–10).
(B) Neutrophil infiltration determined by immu-
nostaining of tumor sections. Gr1+ cells in ten
randomly selected high-power fields (HPFs) per
section (mean ± SEM; n = 4–5).
(C) Neutrophil infiltration determined by MPO
activity in tumor homogenates (mean ± SEM;
n = 7). For all data (A–C), *p < 0.05, **p < 0.01.
(D) Apoptotic cell numbers within tumors in sec-
tions from tumors isolated 7 days after treatment
initiation. Quantification of TUNEL-positive cells in
HPFs of tumor section is shown (n = 6; *p < 0.05).
(E) In vitro analysis of EL4 and EO771 cell death
and senescence after exposure of cells to 4 3 2
Gy/day (mean ± SEM; n = 3).Although apoptosis is a major type of cell death induced by
radiation, especially for lymphoma, alternative cell death modal-
ities or growth arrest can be significant after radiation (Golden
et al., 2012; Kepp et al., 2009). We therefore additionally per-
formed an in vitro analysis of RT-induced effects. EL4 cells,
and for comparison murine mammary carcinoma EO771 cells,
were exposed to 2 Gy/day for 4 days. Analysis of cell death
revealed that about 30% of EL4 cells underwent apoptosis,
with less than 5% of cells becoming necrotic or senescent.
EO771 cells were more resistant to RT-induced apoptosis at
this dose, with a higher proportion of cells becoming senescent
(Figure 3E). These data confirm that a low-dose RT fractionation
scheme results in predominantly apoptotic cell death of EL4 cells
and support our interpretation of in vivo data.822 Cell Reports 8, 818–830, August 7, 2014 ª2014 The AuthorsThe Effect of CR2-Crry on the
Outcome of RT Is Neutrophil
Dependent
Based on the above data showing that
CR2-Crry significantly increased the
number of tumor-infiltrating neutrophils
after RT, we investigated whether the
effect of CR2-Crry on the outcome of
RT was neutrophil dependent. Following
challenge with EL4, mice were depleted
of neutrophils by injection of anti-Ly6G
monoclonal antibody (mAb) (IA8) prior
to initiation of our treatment protocol
and again during the treatment proto-
col to sustain depletion. Depletion was
confirmed by flow cytometry (not shown).
Neutrophil depletion had no discernible
effect on tumor growth in nonirradiated
mice and in mice that received RT alone,
and tumor burden at death or day 15 after
initiation of the treatment protocol was
not significantly different between the RTand RT+IA8 groups. On the other hand, neutrophil depletion
completely abrogated the effect of CR2-Crry on enhancing the
outcome of RT (Figure 4A), and there was no significant differ-
ence in tumor burden between the RT+IA8 and RT+CR2-
Crry+IA8 groups (Figure 4B). Together with the above data on
neutrophil infiltration, these data indicate that the enhancing
effect of CR2-Crry on RT is mediated via the induction of an early
influx of neutrophils into the tumor.
Complement Inhibition Modulates Later Immune Cell
Infiltration after RT
Infiltrating immune cells, including cells associated with adaptive
immunity, were analyzed 14 days after initiation of our treatment
protocol. At this time point, only a comparison between RT- and
Figure 4. Neutrophil Depletion Abrogates
the Enhancing Effect of Complement Inhibi-
tion on the Outcome of RT
Tumor-bearing mice were depleted of neutrophils
using anti-Ly6G mAb IA8 prior to initiation of
therapeutic protocol.
(A) Growth of EL4 tumors over the course of
15 days from initiation of treatment protocol
(individual replicates; n = 4–6).
(B) Tumor size at day 15 posttreatment initiation
(mean ± SEM; n = 4–6; *p < 0.05).RT+CR2-Crry-treated mice was possible due to survival. Similar
to the 7-day analyses reported above, at 14 days posttreatment
initiation, RT+CR2-Crry did not alter numbers of tumor-infil-
trating MDSCs or NK cells compared to RT alone (data not
shown). In contrast to the 7-day data, however, there was a sig-
nificant relative increase in the number of F4/80+ macrophages
with an M1 phenotype (F4/80+, CD11c+, CD206) in tumors
from complement-inhibited mice, a phenotype generally associ-
ated with an antitumor response (Figures 5A and S2). There was
no difference in relative numbers of macrophages with an M2
phenotype (F4/80+, CD11c, CD206+) between the two groups.
Compared to RT alone, RT+CR2-Crry treatment also resultedCell Reports 8, 818–83in significantly higher numbers of infil-
trating mature DCs (CD11c+, CD86+,
and CD80+) and CD8+ T cells (CD3+ and
CD8+) (Figures 5B and 5C). It is important
to note that these differences in infil-
trating immune cells were significant
even though not all mice receiving RT
alone survived to 14 days, and these
data thus represent an analysis of tumors
responding best to RT alone. Further-
more, not all mice receiving RT+CR2-
Crry had detectable tumors at day 14,
and thus analysis of tumors from
this group represents the poorest re-
sponders. There were no differences be-
tween the two groups in the numbers of
CD4+ or CD4+, CD25+, FoxP3+ cells in
tumors (data not shown). Taken together
with the above data, these results indi-
cate that targeted complement inhibition
is modifying the effect of RT by inducing
a proinflammatory and immune-stimula-
tory tumor environment.
The Effect of CR2-Crry on the
Outcome of RT Is Dependent on
Adaptive Immunity
To investigate whether an adaptive im-
mune response is necessary for the effect
of complement inhibition on the outcome
of RT, we repeated our treatment pro-
tocol in Rag1/ mice challenged with
EL4. Tumor growth rates in micereceiving RT alone and RT+CR2-Crry were similar, and CR2-
Crry did not reduce the tumor burden in RT-treated mice as
measured on day 14 after initiation of treatment (Figure 6).
Thus, since CR2-Crry did not enhance the therapeutic effect of
RT in Rag1/ mice, the effect of complement inhibition on
outcome after RT is T and/or B cell dependent. Also, tumor
burden following RT alone was similar in wild-type (WT) and
Rag1/ mice, indicating that T and B cells are not necessary
for the therapeutic response to RT alone.
We also investigated whether RT or RT+CR2-Crry may be
modulating an antitumor antibody response, but we found no ev-
idence of an anti-EL4 IgG response in any treatment group inWT0, August 7, 2014 ª2014 The Authors 823
Figure 5. Complement Inhibition with CR2-Crry Alters the Profile of
Late Tumor-Infiltrating Immune Cells after RT
Determined by flow cytometry 14 days after initiation of treatment protocol.
(A) Percentage of F4/80 positive M1 (F4/80+, CDllc+, CD206) and M2 (F4/80+,
CDllc, CD206+) macrophages (mean ± SEM; n = 3).
(B) Percentage of mature DCs (CDllc+/CD80+/CD86+) (mean ± SEM; n = 3–5).
(C) Percentage of CD8+ T cells (CD3+/CD8+) (mean ± SEM; n = 5–9). For all
analyses, *p < 0.05.
824 Cell Reports 8, 818–830, August 7, 2014 ª2014 The Authorsmice when analyzed 18 days after treatment initiation (data not
shown). We have shown previously that naive C57BL/6 mice
contain anti-EL4 IgM and that this IgM does not affect EL4 tumor
growth (Elvington et al., 2012).
To investigate whether complement inhibition may be
enhancing the outcome of RT by promoting a cellular anti-
tumor immune response, splenocytes were isolated from
mice 18 days after treatment initiation and plated with EL4 cells
as targets. Assay of culture supernatants revealed a significant
increase in IFN-g, IL-10, and IL-6 production from splenocytes
isolated from mice treated with RT+CR2-Crry compared to RT
alone (Figure 7A). Together with the data above showing an
increase in tumor infiltration of CD8+ T cells in mice receiving
RT+CR2-Crry compared to RT alone, the increase in IFN-g
levels suggest that the combined treatment is promoting an
antitumor CD8+ T cell response. Although NK T cells can also
be a source of IFN-g, we did not see any difference in tumor-
infiltrating NK cells between the RT+CR2-Crry and RT groups.
IL-10 is generally considered to be immunosuppressive, but
this cytokine has also been reported to have an antitumor
role, particularly in preventing metastasis (Huang et al., 1996;
Kundu et al., 1996; Kundu and Fulton, 1997) and in enhancing
CD8+ T cell responses (Emmerich et al., 2012). IL-6 promotes
T cell and B cell expansion and T cell activation and has
been shown to have antitumor properties indirectly through
modulation of immune cells (Mule´ et al., 1990). Pooled spleno-
cytes from tumor-bearing mice from all treatment groups
incubated in the absence of EL4 cells ruled out increased
background cytokine production from lymphocytes with tu-
mors, and analysis of EL4 culture supernatants ruled out the
possibility that the tumor cells were producing any of the cyto-
kines analyzed. These data indicate that complement inhibition
is enhancing the therapeutic effect of RT by promoting a sys-
temic antitumor T cell response.
Complement Inhibition Prolongs Survival after RT
Based on evidence of a systemic antitumor immune response,
we investigated the effect of complement inhibition on long-
term outcome after RT. Following administration of our thera-
peutic protocol, outcome was measured in terms of survival,
tumor size on day 11 (the last day of treatment), and at time
of death or sacrifice (due to tumor size). The experiment was
terminated on day 42 after treatment initiation. The median sur-
vival of mice receiving RT+CR2-Crry was significantly extended
compared to mice receiving RT alone (28 versus 17 days),
although only onemouse receiving combined treatment survived
long-term (>42 days) (Figure 7B). Mean tumor size was also
significantly reduced at both day 11 and at death/sacrifice for
mice receiving RT+CR2-Crry compared to RT alone (Figure 7C).
Notably, six out of sevenmice receiving RT alone had to be sacri-
ficed because of tumor size, whereas 8 out of 11 mice receiving
combined treatment had no detectable primary tumor at time of
death. Necropsy revealed lymph node metastasis in most ani-
mals in both treatment groups. As expected from the above
data, no untreated mice survived beyond 8 days (data not
shown). Thus, in the context of RT, CR2-Crry significantly
extended survival time and protected against growth/recurrence
of the primary tumor.
Figure 6. AnAdaptive Immune System IsRequired for the Enhancing
Effect of Complement Inhibition on the Outcome of RT
(A) Growth of EL4 tumors in Rag1/ mice over the course of 14 days from
initiation of treatment protocol (individual replicates; n = 5–8).
(B) Tumor size (mm3) in WT or Rag1/ mice at sacrifice on day 14 (mean ±
SEM; n = 5–8; *p < 0.05, **p < 0.01).Complement Inhibition Improves Therapeutic Outcome
in a Second Cancer Model
All of the above in vivo studies were performed using the EL4
lymphoma model, and to determine whether our findings may
be more generalizable, we also investigated the therapeutic ef-
fect of RT and complement inhibition in a subcutaneous mouse
model of breast cancer. The treatment schedule for RT andCR2-
Crry treatment was similar to that for EL4, except that a higher
fractionated RT dose of 5 Gy was delivered. This higher dose
was used based on above in vitro data showing that EO771 cells
are relatively resistant to low-dose RT-induced apoptosis (see
above), together with additional in vitro data showing that a sin-
gle high dose (30 Gy) resulted in predominantly apoptotic death
of EO771 cells (data not shown). The fractionated dose would
be relevant to whole breast hypofractionation schemes. As
above, tumor size and survival were followed asmarkers of treat-
ment outcome. EO771 tumor growth rate was reduced in mice
receiving localized RT compared to nonirradiated mice, but
cotreatment with RT+CR2-Crry further reduced tumor growth
rate and significantly prolonged survival (Figure S3).
DISCUSSION
With regard to cancer, complement is traditionally thought of as
an effector system of antitumor immunity. The vast majority of
studies involving therapeutic modulation of the complement sys-
tem in cancer are directed at strategies to increase complement
activation by tumor cells. Highlighting this, many antitumormAbs
used clinically are known to utilize complement as an effector
mechanism, and new generations of mAbs are being designed
to increase their complement-activating properties (Kubota
et al., 2009). Indeed, we have also previously demonstrated
that CR2-Fc, a construct that utilizes the same targeting strategy
used in the current study but that delivers a complement acti-
vator (Fc domain) instead of an inhibitor, significantly improves
the outcome of mAb therapy in an EL4 model of metastatic lym-
phoma (Elvington et al., 2012). Nevertheless, in something of a
paradigm shift, recent studies have shown that complement
activation can also promote carcinogenesis. It has been shown
that the complement activation product C5a can promote tumor
growth by suppressing an antitumor T cell response via the
recruitment of Tregs andMDSCs (Corrales et al., 2012; Markiew-
ski et al., 2008) and that complement deficiency or inhibition can
impair tumor growth in the absence of any other treatment, at
least in some mouse models of cancer (Nunez-Cruz et al.,
2012). Other potential protumorigenic mechanisms of comple-
ment include promoting tumor cell proliferation, invasiveness,
and metastasis and enhancing angiogenesis (Pio et al., 2014).
In the current study, complement inhibition alone had no effect
on tumor growth. However, when coadministered with RT,
complement inhibition significantly improved the therapeuticCell Reports 8, 818–830, August 7, 2014 ª2014 The Authors 825
Figure 7. Complement Inhibition Induces
a Systemic Antitumor Response, Extends
Median Survival Time, and Reduces Primary
Tumor Size/Recurrence after RT
(A) Cytokine production was measured from
splenocytes isolated from RT- and RT+CR2-Crry-
treated groups and incubated with EL4 target
cells. Also shown is cytokine production from
splenocytes from RT- and RT+CR2-Crry-treated
tumor-bearingmice cultured in the absence of EL4
cells (unstimulated) and from EL4 cells cultured
alone (EL4). Splenocytes were isolated 18 days
after initiation of treatment protocol and cytokines
assayed by ELISA (mean ± SEM; n = 5–6; *p <
0.05, **p < 0.01).
(B) Survival of mice after treatment protocol (n =
7–11; *p < 0.05).
(C) Tumor size (mm3) on the last day of treatment
(day 11) and at death or sacrifice (due to tumor
size) (mean ± SEM; n = 7–11; *p < 0.05).outcome of RT. Although complement inhibition is normally anti-
inflammatory, in the context of localized RT, complement inhibi-
tion was found to promote inflammation within the tumor, induce
an early influx of neutrophils, and promote a systemic antitumor
immune response. We focused on a lymphoma model, since
lymphoma represents a generally radiosensitive type of cancer,
with induction of apoptosis a known mechanism of tumor cell
killing (Ganem et al., 2010). Localized fractionated RTwas shown
to result in complement activation within the tumor environment,
and the subsequent targeted inhibition of complement in the tu-
mor resulted in an early increase in the level of apoptotic tumor
cells after initiation of treatment. These data, together with previ-
ous data demonstrating an important role for C3 opsonins
in the phagocytosis of apoptotic cells (Mevorach et al., 1998),
indicate a therapeutic mechanism involving reduced comple-
ment-dependent clearance of apoptotic cells. Failure to clear
apoptotic cells is associated with inflammation and the genera-
tion of an immunostimulatory environment, with a reservoir of
modified immunological self-antigens that can provide a chal-
lenge to tolerance (Fadok et al., 1998; Gallucci et al., 1999;
Peng et al., 2007).
The increase in early neutrophil recruitment into tumors was
essential for the enhanced therapeutic effect of CR2-Crry treat-
ment on RT, since neutrophil depletion ablated the effect of CR2-
Crry. Although neutrophils are a hallmark of acute inflammation
and provide an important host defense mechanism, they are
not generally considered to be potent antitumor effector cells.
They have, nevertheless, been shown to directly kill tumor cells
by oxidative damage, induction of apoptosis via Fas ligand,
and by antibody-dependent cellular cytotoxicity (Fridlender
and Albelda, 2012). However, in the current study, a functional
adaptive immune system was also required for the enhanced
therapeutic effect of CR2-Crry, as demonstrated by experiments
performed in Rag1/mice that lack T and B cells. Interestingly,
one of the most successful antitumor immunotherapies to date,826 Cell Reports 8, 818–830, August 7, 2014 ª2014 The AuthorsMycobacterium bovis Bacillus Calmette-Guerin (BCG), also de-
pends on early neutrophil infiltration that directs the subsequent
cellular-mediated antitumor immune response (Suttmann et al.,
2006). Neutrophils express the complement receptors C3aR
and C5aR, and complement activation can have a direct effect
on neutrophil recruitment through C3a/C5a mobilization, with
C5a-mediated recruitment of neutrophils demonstrated in
several disease models (Godau et al., 2004; Mueller et al.,
2013). However, since CR2-Crry inhibits complement activation
and C5a generation in the tumor after RT, the increased infiltra-
tion of neutrophils is unlikely to be due to C5a-medited recruit-
ment and is thus likely due to cytokine/chemokine-mediated
migration. Indeed, the tumor environment early after combined
RT+CR2-Crry treatment was characterized by significantly
increased levels of IFN-g, IL-6, and IL-17 compared to other
treatment groups. IL-17 recruits neutrophils to sites of inflamma-
tion through induced production of IL-6 as well as other neutro-
phil chemoattractants (Laan et al., 1999; Miyamoto et al., 2003).
Nevertheless, the data do not rule out the possibility that the
increased neutrophil numbers in RT+CR2-Crry-treated mice
are the source of the increased cytokines, rather than the cyto-
kines mediating neutrophil recruitment. Tumor-infiltrating neu-
trophils were analyzed by anti-GR1 immunohistochemistry,
MPO activity, and functionally by depletion with anti-Ly6G, and
we note that these analyses cannot definitively rule out granulo-
cytic MDSCs, although Ly6G is expressed only by a subset of
MDSCs. Definitive differentiation would require functional anal-
ysis, but in this context, increased infiltration is associated with
an antitumor response, not immunosuppression, and depletion
of Ly6G+ cells ablates the antitumor response.
Although radiation alone can significantly modify the tumor
environment, radiation alone is not usually able to induce an
effective antitumor immune response. However, clinical and
experimental evidence suggests that RT can function as an im-
mune adjuvant, and increased T cell infiltration and abscopal
effects indicative of systemic immunity have been observed
when RT is combined with some immunotherapies (Demaria
and Formenti, 2012; Dewan et al., 2009; Dovedi et al., 2013;
Hodge et al., 2008; Lee et al., 2009; Lugade et al., 2005; Postow
et al., 2012). T cells have been shown to play a key role in anti-
tumor immune responses induced by RT, and targeting T cell
costimulatory (e.g., CD137, CD40) or coinhibitory (e.g., CTLA-
4, PD-1) receptors in combination with RT has been shown to
produce durable antitumor immune responses (reviewed in
Demaria and Formenti, 2012; Hodge et al., 2008). Another
approach that has been used to modify RT-induced antitumor
immunity is the stimulation of dendritic cells (DCs), and activated
DCs are important to support antitumor CD8+ T cells following
RT (Finkelstein and Fishman, 2012). Here, we demonstrate that
compared to localized RT alone, combination treatment with a
targeted complement inhibitor increases DC maturation and
CD8+ T cell infiltration into tumors. In addition to increased
CD8+ T cell infiltration, splenocytes isolated from mice receiving
the combined treatment generate increased IFN-g when stimu-
lated with tumor cells. These data indicate immune response
modification by RT+CR2-Crry, with the promotion of a systemic
antitumor response characterized by DC maturation that sup-
ports the induction of anti-EL4-specific CD8+ T cells.
With regard to the use of CR2-Crry, the safety and pharmaco-
kinetics of this inhibitor have been characterized previously in a
model of inflammatory disease (Atkinson et al., 2005). Unlike
complement inhibition with an untargeted counterpart, the tar-
geting of CR2-Crry to sites of complement activation obviates
the need for systemic inhibition and does not impact host sus-
ceptibility to infection; a potentially important consideration for
patients receiving RT for lymphoma. Contributing to this safety
aspect is the short circulatory half-life of CR2-Crry (8.7 hr) (Atkin-
son et al., 2005) with retention at sites of complement activation
(Atkinson et al., 2008). Humanized counterparts of CR2-Crry are
under clinical development. The rationale for using a Crry-based
inhibitor is that Crry functions at the C3 activation step of all three
complement-activation pathways and inhibits the generation of
C3 opsonins that have been shown to be involved in apoptotic
cell uptake by phagocytes. Crry is a structural and functional
analog of human CR1. Other complement inhibitors that are
specific for a certain activation pathway are likely to provide
less complete protection against C3 opsonization, and inhibitors
that function later in the pathway, such as C5mAb or a C5b-9 in-
hibitor, would not be expected to inhibit C3 opsonization.
Although combined treatment significantly extended survival
and improved tumor burden compared to RT alone, it did not
provide long-term protection. It is interesting, however, that
mice treated with RT alone had recurrence of the primary tumor
following cessation of treatment, whereas mice cotreated with
CR2-Crry were protected from primary tumor relapse, even
though they eventually succumbed to disease. It is likely that
alternate dosing strategies will differentially modulate antitumor
immunity and a potential abscopal effect. Here, we used low-
dose fractionated RT, a conventional clinical approach for lym-
phoma, although in some cancer models, there is evidence
that high single dose of ablative radiation is more immunostimu-
latory and produces a more robust T cell response, whereas
fractionated RT is immunosuppressive (Burnette et al., 2011;Lee et al., 2009). In contrast, however, there is also evidence
that fractionated RT is superior to single high-dose RT at
enhancing antitumor immunity in combination with antibody
therapy (Dewan et al., 2009; Dovedi et al., 2013). Regardless,
here we present the use of a targeted complement inhibitor to
promote, rather than suppress, inflammation and demonstrate
that complement inhibition modulates antitumor immunity and
enhances outcome after RT. Even though combined treatment
did not provide complete long-term protection, controlling local
disease and accelerating or completing the clearance of a tumor
that is being irradiated, as we show here, has the potential
for major clinical impact. How different RT dosing strategies,
as well as different apoptosis-based therapies, such as chemo-
therapy, respond to complement inhibition deserves further
study.
EXPERIMENTAL PROCEDURES
Cell Line
The EL4 mouse lymphoma cell line was purchased from ATCC and grown
in RPMI 1640 with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 mg/ml streptomycin at 37C in 5% CO2.
Mice
Wild-type C57BL/6 mice and Rag/mice on C57BL/6 background were pur-
chased from The Jackson Laboratory. Male mice between the ages of 8 and
10 weeks were used for all experiments. The Medical University of South
Carolina Institutional Animal Care and Use Committee, in accordance with
the NIHGuide for the Care and Use of Laboratory Animals, approved all animal
procedures.
Subcutaneous Tumor Models and Treatment Protocol
Mice were injected subcutaneously on the right flank with 5 3 105 EL4 cells.
Twelve days after tumor challenge, localized RT was initiated. Mice received
a total dose of 15 Gy in 1.5 Gy fractions (see below). The recombinant protein
CR2-Crry was prepared and purified as described previously (Atkinson et al.,
2005), and mice were treated with 0.25 mg of CR2-Crry 24 hr after the first
fraction of RT and every 72 hr thereafter for the duration of treatment (see
schematic, Figure S1). Depending on the experiment, surviving mice were
sacrificed at different time points after treatment initiation or when tumor
size exceeded 4,000 mm3 or when mice showed signs of severe stress.
In a second model, mice were injected subcutaneously on the right flank
with 5 3 105 EO771 cells (C57BL/6 breast carcinoma cell line) and treated in
a similar protocol, except that 5 Gy fractions were delivered.
Irradiation Technique and Radiation Dosimetry
The mice received localized RT using the following irradiation technique. The
mice were placed in a pie-shaped holder that held eight mice in equally sized
sectors. A 6-mm-thick lead shield with eight 1.75-cm-diameter holes was
placed on top of the holder. The mice were aligned such that only their flank
tumors were exposed through the holes. A slab of tissue-equivalent material
with a thickness of 1 cm was placed on top of the lead before irradiation.
The mice were irradiated with a Varian 21eX clinical linear accelerator using
a 9 MeV electron beam and a 253 25 cm2 open applicator. The mouse holder
was centered under the applicator at a source-to-surface distance of 100 cm,
measured to the top of the lead shield. The prescribed dose was 1.5 Gy per
fraction for EL4 and 5 Gy per fraction for EO771 at a depth of 10 mm below
the surface of the tumor. Dosimetry was performed with radiochromic film to
determine the number of monitor units (MU) needed to deliver the prescribed
dose.
In Vivo Imaging
The NIR dye XenoLight CF 750 (PerkinElmer) was used to label CR2-Crry
per the manufacturer’s instructions. Fluorescent multispectral images wereCell Reports 8, 818–830, August 7, 2014 ª2014 The Authors 827
obtained using the Maestro In-Vivo Imaging System (PerkinElmer). Spectral
libraries were manually computed using the Maestro software, with each
tissue used as its own background control.
The fluorescence images of the EL4 tumor bearing mice, with or without RT
(4 doses of 1.5 Gy) were acquired 1 hr, 5 hr, 24 hr, and 48 hr postinjection of
fluorescently labeled CR2-Crry (0.25 mg). To evaluate signal intensities, tumor
regions were selected and the total fluorescence signal from those areas
determined. The average signal in the selected region, defined in photons
measured at the surface of the animal, was divided by the area (in pixels) as
well as the exposure time (in seconds). The average signal (3106 photons/
cm2/s) of CR2-Crry within the tumors was then divided by the size of the tumor
(mm3). The final average signal (3106 photons/cm2/s)/mm3 of the CR2-Crry
within the tumors was compared to between the two groups (CR2-Crry only
versus RT+CR2-Crry). Using the Compare Images tool on the Maestro soft-
ware, grayscale images collected over the five time periods were compared,
accounting for differences in intensity due to bit depth, exposure time, and
binning. Pseudocolor was applied to the grayscale images using the ‘‘Jet’’
color map.
Analysis of Complement Activation and Apoptosis
For analysis of C3d deposition, tumors were removed 24 hr after first CR2-Crry
treatment. Tumors were formalin fixed and paraffin embedded, and 5 mm tis-
sue sections cut. Sections were analyzed by immunohistochemistry with anti-
C3d (R&DSystems) as previously described (Atkinson et al., 2009). Slideswere
analyzed by light microscopy and a blinded observer quantified positive cells
on a scale of 0 to 3 in five high-powered fields per slide. C5a levels in tumor
homogenates were quantified by a mouse C5a ELISA according to the manu-
facturer’s instructions (BD Pharmingen).
For analysis of apoptotic tumor cells, mice were sacrificed and tumors
removed 7 days posttreatment initiation. Paraffin-embedded sections were
analyzed for apoptotic cell number by TUNEL staining using the Apoptag kit
from Millipore per the manufacturer’s instructions. Slides were analyzed by
light microscopy and a blinded observer quantified positive cells in ten high-
powered fields per slide. For in vitro analysis of cell death after radiation expo-
sure, early log-phase EL4 or EO771 (mousemammary carcinoma) cells, at 13
106 cells/ml in RPMI 1640, 10% FBS, were exposed to 2 Gy/day for 4 days.
Twenty-four hours after last exposure, cells were stained using the FITC
Annexin V Apoptosis Detection kit (BD Pharmingen) and propidium iodide to
determine apoptosis and necrosis according to the manufacturer’s instruc-
tions. Senescence was determined using cytospin slides with staining for
b-galactosidase using a kit from Cell Signaling Technology.
Neutrophil Depletion
Neutrophils were specifically depleted by an anti-Ly6G mAb, IA8, which
preserves other cell populations expressing Gr1+ (Daley et al., 2008). IA8
(500 mg 100 ml intraperitoneally) was injected 24 hr prior to the first irradiation
dose and 24 hr and 5 days after the first irradiation dose. Depletion was
confirmed over the course of treatment by assaying Gr1+ cells in the blood
by flow cytometry (anti-Gr1 mAb, BD Biosciences).
Analysis of Neutrophil Infiltration
Immunohistochemistry staining for Gr1+ cells (anti-Gr1, BD Biosciences) was
performed on paraffin-embedded tumor sections. Positive cells were visual-
ized by light microscopy and quantified by a blinded observer. Levels of
MPO were determined in tumor homogenates using a MPO activity assay
from Northwest Life Science Specialties according to the manufacturer’s
instructions.
Cytokines and Analysis of Immune Cell Populations
Levels of IFN-g, IL-10, IL-6, and IL-17 in homogenates of tumors isolated
7 days after treatment initiation were assayed by ELISA (BD Biosciences;
except IL-17 [R&D Systems]). Immune cell populations within the tumor
were analyzed at 7 or 14 days posttreatment initiation by flow cytometry. Stain-
ing for specific cell types were performed using the following antibodies:
for CD8+ T cells, anti-CD3e and anti-CD8; for mature DCs, anti-CD11c, anti-
CD80, and anti-CD86; for M1/M2 macrophages, anti-F4/80 (total), anti-
CD11c (M1), and anti-CD206 (M2). M1 macrophages were classified as (F4/828 Cell Reports 8, 818–830, August 7, 2014 ª2014 The Authors80+, CD11c+, CD206) and M2 macrophages as (F4/80+, CD11c, CD206+);
for MDSCs, anti CD11b, anti-Gr1, with granulocytic and myeloid cells distin-
guished by side scatter. All antibodies for flow cytometry were purchased
from BD Biosciences with the exception of anti-CD206 (BioLegend). Samples
were analyzed on a BD LSRFortessa flow cytometer (BD Biosciences) and
analyzed with FlowJo 9.3.3 software (TreeStar).
Analysis of Antitumor Cellular Immune Response
Total splenocytes were isolated from mice 18 days after treatment initiation
and plated either without EL4 cells or with EL4 tumor cells as targets at a
10:1 ratio. Coculture supernatant was collected 72 hr later and assayed for
levels of IFN-g, IL-10, and IL-6 by ELISA (BDBiosciences). Culture supernatant
from cultured EL4 cells only was also analyzed to rule out the possibility that
the cancer cells were producing any of the cytokines analyzed.
Statistical Analysis
GraphPad Prism version 5 was used for statistical analysis. Analysis of survival
curves was done by the log-rank test. Parametrical analysis was done using a
one-way ANOVA with the Bonferroni multiple comparison test. Nonparametric
analysis (histology) was done using one-way ANOVA with Dunn’s multiple
comparison test. Comparisons between two groups over timewere performed
by two-way ANOVA. Comparisons between two groups were performed by
the Student’s t test (parametric) or Mann-Whitney U test (nonparametric). A
p value < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2014.06.051.
AUTHOR CONTRIBUTIONS
M.E. and M.S. designed and performed experiments, analyzed data, and
wrote the manuscript. X.Y. prepared and characterized essential reagents.
K.L., D.J., D.M., and K.V. performed experiments, provided expertise in
radiation therapy, and interpreted data. C.W. performed experiments and
analyzed data. S.T. designed experiments, interpreted data, and wrote the
manuscript. All coauthors reviewed the manuscript prior to submission.
ACKNOWLEDGMENTS
This work was supported by a grant from the NIH (RO1CA158179). We thank
Ms. Emily Paulling for expert technical assistance. S.T. holds licensed patents
for CR2-targeted complement inhibitors.
Received: March 20, 2014
Revised: April 17, 2014
Accepted: June 25, 2014
Published: July 24, 2014
REFERENCES
Atkinson, C., Song, H., Lu, B., Qiao, F., Burns, T.A., Holers, V.M., Tsokos, G.C.,
and Tomlinson, S. (2005). Targeted complement inhibition by C3d recognition
ameliorates tissue injury without apparent increase in susceptibility to infec-
tion. J. Clin. Invest. 115, 2444–2453.
Atkinson, C., Qiao, F., Song, H., Gilkeson, G.S., and Tomlinson, S. (2008). Low-
dose targeted complement inhibition protects against renal disease and other
manifestations of autoimmune disease in MRL/lpr mice. J. Immunol. 180,
1231–1238.
Atkinson, C., Varela, J.C., and Tomlinson, S. (2009). Complement-dependent
inflammation and injury in a murine model of brain dead donor hearts. Circ.
Res. 105, 1094–1101.
Burnette, B.C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N.N., Weichsel-
baum, R.R., Fu, Y.X., and Auh, S.L. (2011). The efficacy of radiotherapy relies
upon induction of type i interferon-dependent innate and adaptive immunity.
Cancer Res. 71, 2488–2496.
Chen, Y., Park, Y.B., Patel, E., and Silverman, G.J. (2009). IgM antibodies to
apoptosis-associated determinants recruit C1q and enhance dendritic cell
phagocytosis of apoptotic cells. J. Immunol. 182, 6031–6043.
Corrales, L., Ajona, D., Rafail, S., Lasarte, J.J., Riezu-Boj, J.I., Lambris, J.D.,
Rouzaut, A., Pajares, M.J., Montuenga, L.M., and Pio, R. (2012). Anaphylatoxin
C5a creates a favorable microenvironment for lung cancer progression.
J. Immunol. 189, 4674–4683.
Daley, J.M., Thomay, A.A., Connolly, M.D., Reichner, J.S., and Albina, J.E.
(2008). Use of Ly6G-specific monoclonal antibody to deplete neutrophils in
mice. J. Leukoc. Biol. 83, 64–70.
Demaria, S., and Formenti, S.C. (2012). Role of T lymphocytes in tumor
response to radiotherapy. Front Oncol 2, 95.
Dewan, M.Z., Galloway, A.E., Kawashima, N., Dewyngaert, J.K., Babb, J.S.,
Formenti, S.C., and Demaria, S. (2009). Fractionated but not single-dose
radiotherapy induces an immune-mediated abscopal effect when combined
with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379–5388.
Dovedi, S.J., Melis, M.H., Wilkinson, R.W., Adlard, A.L., Stratford, I.J., Honey-
church, J., and Illidge, T.M. (2013). Systemic delivery of a TLR7 agonist in com-
bination with radiation primes durable antitumor immune responses in mouse
models of lymphoma. Blood 121, 251–259.
Elvington, M., Huang, Y., Morgan, B.P., Qiao, F., van Rooijen, N., Atkinson, C.,
and Tomlinson, S. (2012). A targeted complement-dependent strategy to
improve the outcome of mAb therapy, and characterization in a murine model
of metastatic cancer. Blood 119, 6043–6051.
Emmerich, J., Mumm, J.B., Chan, I.H., LaFace, D., Truong, H., McClanahan,
T., Gorman, D.M., and Oft, M. (2012). IL-10 directly activates and expands
tumor-resident CD8(+) T cells without de novo infiltration from secondary
lymphoid organs. Cancer Res. 72, 3570–3581.
Fadok, V.A., Bratton, D.L., Konowal, A., Freed, P.W., Westcott, J.Y., and
Henson, P.M. (1998). Macrophages that have ingested apoptotic cells
in vitro inhibit proinflammatory cytokine production through autocrine/para-
crine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101,
890–898.
Finkelstein, S.E., and Fishman, M. (2012). Clinical opportunities in combining
immunotherapy with radiation therapy. Front Oncol 2, 169.
Fridlender, Z.G., and Albelda, S.M. (2012). Tumor-associated neutrophils:
friend or foe? Carcinogenesis 33, 949–955.
Gallucci, S., Lolkema, M., and Matzinger, P. (1999). Natural adjuvants: endog-
enous activators of dendritic cells. Nat. Med. 5, 1249–1255.
Ganem, G., Cartron, G., Girinsky, T., Haas, R.L., Cosset, J.M., and Solal-
Celigny, P. (2010). Localized low-dose radiotherapy for follicular lymphoma:
history, clinical results, mechanisms of action, and future outlooks. Int. J.
Radiat. Oncol. Biol. Phys. 78, 975–982.
Gershov, D., Kim, S., Brot, N., and Elkon, K.B. (2000). C-Reactive protein
binds to apoptotic cells, protects the cells from assembly of the terminal
complement components, and sustains an antiinflammatory innate immune
response: implications for systemic autoimmunity. J. Exp. Med. 192, 1353–
1364.
Godau, J., Heller, T., Hawlisch, H., Trappe, M., Howells, E., Best, J., Zwirner,
J., Verbeek, J.S., Hogarth, P.M., Gerard, C., et al. (2004). C5a initiates the in-
flammatory cascade in immune complex peritonitis. J. Immunol. 173, 3437–
3445.
Golden, E.B., Pellicciotta, I., Demaria, S., Barcellos-Hoff, M.H., and Formenti,
S.C. (2012). The convergence of radiation and immunogenic cell death
signaling pathways. Front Oncol 2, 88.
Hodge, J.W., Guha, C., Neefjes, J., and Gulley, J.L. (2008). Synergizing radia-
tion therapy and immunotherapy for curing incurable cancers. Opportunities
and challenges. Oncology (Williston Park) 22, 1064–1070, discussion 1075,
1080–1081, 1084.Huang, S., Xie, K., Bucana, C.D., Ullrich, S.E., and Bar-Eli, M. (1996). Inter-
leukin 10 suppresses tumor growth and metastasis of human melanoma cells:
potential inhibition of angiogenesis. Clin. Cancer Res. 2, 1969–1979.
Kemper, C., Mitchell, L.M., Zhang, L., and Hourcade, D.E. (2008). The
complement protein properdin binds apoptotic T cells and promotes
complement activation and phagocytosis. Proc. Natl. Acad. Sci. USA 105,
9023–9028.
Kepp, O., Tesniere, A., Schlemmer, F., Michaud, M., Senovilla, L., Zitvogel, L.,
and Kroemer, G. (2009). Immunogenic cell death modalities and their impact
on cancer treatment. Apoptosis 14, 364–375.
Korb, L.C., and Ahearn, J.M. (1997). C1q binds directly and specifically to
surface blebs of apoptotic human keratinocytes: complement deficiency
and systemic lupus erythematosus revisited. J. Immunol. 158, 4525–4528.
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., and Hanai, N. (2009).
Engineered therapeutic antibodies with improved effector functions. Cancer
Sci. 100, 1566–1572.
Kundu, N., and Fulton, A.M. (1997). Interleukin-10 inhibits tumor metastasis,
downregulates MHC class I, and enhances NK lysis. Cell. Immunol. 180,
55–61.
Kundu, N., Beaty, T.L., Jackson, M.J., and Fulton, A.M. (1996). Antimetastatic
and antitumor activities of interleukin 10 in a murine model of breast cancer.
J. Natl. Cancer Inst. 88, 536–541.
Laan, M., Cui, Z.H., Hoshino, H., Lo¨tvall, J., Sjo¨strand, M., Gruenert, D.C.,
Skoogh, B.E., and Linde´n, A. (1999). Neutrophil recruitment by human IL-17
via C-X-C chemokine release in the airways. J. Immunol. 162, 2347–2352.
Lee, Y., Auh, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M.,
Sharma, R., Chin, R., Tu, T., et al. (2009). Therapeutic effects of ablative
radiation on local tumor require CD8+ T cells: changing strategies for cancer
treatment. Blood 114, 589–595.
Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., and Lord,
E.M. (2005). Local radiation therapy of B16 melanoma tumors increases the
generation of tumor antigen-specific effector cells that traffic to the tumor.
J. Immunol. 174, 7516–7523.
Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K.,
Koutoulaki, A., Gerard, C., Coukos, G., and Lambris, J.D. (2008). Modulation
of the antitumor immune response by complement. Nat. Immunol. 9, 1225–
1235.
Mevorach, D., Mascarenhas, J.O., Gershov, D., and Elkon, K.B. (1998). Com-
plement-dependent clearance of apoptotic cells by human macrophages.
J. Exp. Med. 188, 2313–2320.
Miyamoto, M., Prause, O., Sjo¨strand, M., Laan, M., Lo¨tvall, J., and Linde´n, A.
(2003). Endogenous IL-17 as a mediator of neutrophil recruitment caused by
endotoxin exposure in mouse airways. J. Immunol. 170, 4665–4672.
Mueller, M., Herzog, C., Larmann, J., Schmitz, M., Hilfiker-Kleiner, D., Gess-
ner, J.E., and Theilmeier, G. (2013). The receptor for activated complement
factor 5 (C5aR) conveys myocardial ischemic damage bymediating neutrophil
transmigration. Immunobiology 218, 1131–1138.
Mule´, J.J., McIntosh, J.K., Jablons, D.M., and Rosenberg, S.A. (1990). Anti-
tumor activity of recombinant interleukin 6 in mice. J. Exp. Med. 171, 629–636.
Navratil, J.S., Watkins, S.C., Wisnieski, J.J., and Ahearn, J.M. (2001). The glob-
ular heads of C1q specifically recognize surface blebs of apoptotic vascular
endothelial cells. J. Immunol. 166, 3231–3239.
Nunez-Cruz, S., Gimotty, P.A., Guerra, M.W., Connolly, D.C., Wu, Y.Q.,
DeAngelis, R.A., Lambris, J.D., Coukos, G., and Scholler, N. (2012). Genetic
and pharmacologic inhibition of complement impairs endothelial cell function
and ablates ovarian cancer neovascularization. Neoplasia 14, 994–1004.
Ogden, C.A., deCathelineau, A., Hoffmann, P.R., Bratton, D., Ghebrehiwet, B.,
Fadok, V.A., and Henson, P.M. (2001). C1q and mannose binding lectin
engagement of cell surface calreticulin and CD91 initiates macropinocytosis
and uptake of apoptotic cells. J. Exp. Med. 194, 781–795.
Peng,Y.,Martin,D.A.,Kenkel, J.,Zhang,K.,Ogden,C.A., andElkon,K.B. (2007).
Innate and adaptive immune response to apoptotic cells. J. Autoimmun. 29,
303–309.Cell Reports 8, 818–830, August 7, 2014 ª2014 The Authors 829
Pio, R., Corrales, L., and Lambris, J.D. (2014). The role of complement in tumor
growth. Adv. Exp. Med. Biol. 772, 229–262.
Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S.,
Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012). Immunologic corre-
lates of the abscopal effect in a patient with melanoma. N. Engl. J. Med.
366, 925–931.
Silverman, G.J., Gro¨nwall, C., Vas, J., and Chen, Y. (2009). Natural autoanti-
bodies to apoptotic cell membranes regulate fundamental innate immune
functions and suppress inflammation. Discov. Med. 8, 151–156.830 Cell Reports 8, 818–830, August 7, 2014 ª2014 The AuthorsSong, H., He, C., Knaak, C., Guthridge, J.M., Holers, V.M., and Tomlinson, S.
(2003). Complement receptor 2-mediated targeting of complement inhibitors
to sites of complement activation. J. Clin. Invest. 111, 1875–1885.
Suttmann, H., Riemensberger, J., Bentien, G., Schmaltz, D., Sto¨ckle, M., Joc-
ham, D., Bo¨hle, A., and Brandau, S. (2006). Neutrophil granulocytes are
required for effective Bacillus Calmette-Gue´rin immunotherapy of bladder
cancer and orchestrate local immune responses. Cancer Res. 66, 8250–8257.
Tenner, A.J. (1998). C1q receptors: regulating specific functions of phagocytic
cells. Immunobiology 199, 250–264.
